In this regard, Lundberg et al reported that SOX2-positive colorectal cancer patients do not survive as long as SOX2-negative colorectal cancer patients, and this differential is larger for patients with BRAFV600E mutations who survive for substantially shorter periods than those who are SOX2-positive, but lack the BRAF mutation [160]. This evidence concerns the gene SOX2 and colorectal cancer.